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Abstract
Background: Generalized anxiety disorder has a strong impact on health-related quality of life. For this reason, it
seems relevant to develop strategies allowing early diagnoses in order to promote appropriate treatments. The
objective of this study was to culturally adapt and validate the GAD-7 for the Portuguese patients with generalized
anxiety disorder.
Methods: For the cultural adaptation of the Portuguese version of the GAD-7 scale we started with a previous
translation made by Mapi Institute and decided to perform a clinical review followed by a cognitive debriefing
with patients. Once piloted, this version was then tested in a larger sample for feasibility and reliability (1-week
test-retest). Construct validity was assessed by the relationship between GAD-7 and socio-demographic and
clinical variables. Its unidimensionality was tested by principal component factor analysis. Criterion validity was
assessed by comparing GAD-7 scores with those obtained by HADS, and EQ-5D. STAI was mainly used as a
screening indicator for patient inclusion.
Results: GAD-7 was considered feasible with a mean completion time of 2.3 minutes and no major floor or
ceiling effects. We found an excellent Cronbach’s alpha internal consistency score (0.880) and the test-retest and
interclass correlation coefficients were also very good. Regarding the construct validity, younger patients, those
with higher education, employed and without anxiety symptoms revealed lower GAD-7 scores, meaning better
health. The unidimensionality of GAD-7 index was also confirmed by principal component factor analysis. At last,
GAD-7 was significantly correlated with other health outcome indices and the classification levels created by it
and by HADS showed to be dependent.
Conclusion: The excellent metric properties confirmed the cultural adaptation and validity of GAD-7 into Portuguese
population, allowing the clinicians an early detection and treatment of these patients.
Keywords: Generalized anxiety disorder (GAD), Portuguese version, Validation
Introduction
Anxiety is the manifestation of an emotion, characterized
by a physical and psychological discomfort described by
individuals as a feeling of restlessness, nervousness and
excessive concern [1-3]. Anxiety disorders are the most
common psychiatric disorders in Europe, with an annual
prevalence of 12% in the European adult population and a
lifetime prevalence of 5%.
Generalized anxiety disorder (GAD) was included for
the first time in the third edition of the DSM in 1980
[4]. Since then, its definition has been modified on
subsequent DSM-III-R, DSM-IV and DSM-IV TR [5-8].
GAD is clearly distinguished from other anxiety and
depression disorders in both DSM-IV-TR and ICD-10.
GAD is defined, by the text revision of the fourth
edition of Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR), as excessive anxiety and worry
about several events or activities for most days during at
least at 6-month period. The worry is difficult to control
and is associated with somatic symptoms such as muscle
tension, irritability, difficulty sleeping and restleness. The
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anxiety is distressing and produces impairment in
important areas of the person’s life [9].
GAD lifetime prevalence was estimated on 2.8% in
Europe [3,10,11]. The ratio of women to men with the
disorder is about 2 to 1. This disorder has probably the
highest comorbility with another mental disorder, such
as depressive disorders, specific and social phobia, panic
disorder and substance-related disorder [9].
Portugal has an annual mental illness prevalence of
22.9%, higher than other European countries. The ques-
tion of how to explain such a high prevalence, different
from what was found in other Southern European coun-
tries still remains to be answered. Could it be the expos-
ure to more vulnerable and/or less protective factors in
relation to mental illness, leading to a higher frequency
of psychiatric disorder among the Portuguese popula-
tion? If so, what is the nature and the role of the factors
involved? Is it possible that these results can be
explained by the existence in the Portuguese culture of
specific patterns of perception and manifestation of
emotional complaints leading to increased expression of
symptoms that are the basis of the diagnosis of mental
illness? At present, there are no definitive answers to
these questions [12]. In addition, between 2008 and
2009, anxiety disorders were one of the most common
disorders within the Portuguese population, with an
annual prevalence of 16.5%. It was also found that 33.6%
patients with a severe psychiatric disorder in Portugal
did not receive any kind of treatment [12].
Although the exact cause of GAD cannot be specified,
there are population groups at greater risk with high
comorbidity [10]. The highest prevalence occurs in the
45–59 age group, and it was more common in women
(7%) than in men (4%). Other important predictors
include being separated, widowed or divorced, un-
employed or housewife [13,14].
Several studies have suggested that GAD negatively
impacts on activities of daily life and patients’ health-
related quality of life (HRQoL), and results in the possi-
bility of decreased lifetime work productivity, thereby
having a significant economic burden [15-18]. The
literature showed that the strong impact of GAD on
HRQoL is greater than the one observed in major de-
pression [19], seeming relevant the development of strat-
egies allowing early diagnoses, in order to promote
appropriate treatment.
Taking into account the evaluation of anxiety and the in-
struments internationally developed, surprisingly there
were no instrument culturally adapted and appropriately
validated for the Portuguese population [20]. Therefore the
objective of this study was to culturally adapt and validate
the GAD-7 scale to the European Portuguese population
and to assess the psychometric properties of the adapted
version in terms of feasibility, reliability and validity.
Methods
Description of GAD-7
The GAD-7 is a self-administered patient questionnaire
normally used as a screening tool and as a severity
measure for patients with generalized anxiety disorder
[21,22]. It has a unidimensional structure matching the
original structure of DSM-IV-TR diagnostic criteria with
all items measuring the same concept and in the same
direction. It is composed by seven items corresponding
to symptoms based on the criteria for GAD in the Diag-
nostic and Statistical Manual of Mental Disorders [5-8]
including (1) feeling nervous, anxious or on edge, (2)
not being able to stop or control worrying, (3) worrying
too much about different things, (4) trouble relaxing, (5)
being so restless that it is hard to sit still, (6) becoming
easily annoyed or irritable, and (7) feeling afraid as if
something awful might happen. The time period for the
measurement is the two previous weeks and, through a
4-point Likert scale from ‘not at all’ to ‘nearly every day’,
it is asked how often the patient has been bothered by
any of the presented problems.
The GAD-7 index is obtained by adding the scores
from the questionnaire, after having assigned 0 to the
least severe situation, 3 to the most severe one, and 1
and 2 to the intermediate ones. The cut off points 5, 10
and 15 allow us to classify the anxiety as none/normal
(0–4), mild (5–9), moderate (10–14), and severe (15–21).
In general, anyone who scores 8 or above can be consid-
ered as having significant anxiety symptoms [23].
Linguistic and semantic equivalence
We based our study on the official Portuguese version
copyrighted by Pfizer and already translated by Mapi
Research Institute, a leading patient-centered research
company. The linguistic validation of the GAD-7 into
Portuguese aimed to obtain a conceptually equivalent
version easily understood by patients. With the collabor-
ation of the instrument’s developer, this rigorous meth-
odology involved a process which comprised several
steps: forward translations by two qualified translators, a
reconciliated version, a translation by another qualified
translator, and a cognitive debriefing on 5 healthy sub-
jects [24,25].
However, to complete the linguistic and cultural adap-
tation we decided to perform a clinical review and a cog-
nitive debriefing with patients. Both were considered a
means to test the instrument’s content validity, i.e., to
evidence its suitability to the specific purpose. So, for a
clinical review, we first asked a committee composed by
both forward translators, six psychiatrists (authors), a
medical advisor from Pfizer (author) and two other psy-
chiatrists to clinically comment the Portuguese transla-
tion, taking into account the original one in English.
Based on their remarks, we then made changes in the
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Portuguese version and performed a cognitive debriefing
interviewing ten patients with the purpose of finding the
presence of any problems of clarity, understandability
and redundancy of the items. To assess the feasibility of
GAD-7 we recorded the time taken by patients to fill the
questionnaire, as well as the difficulties patients had in
answering it. Missing values, floor and ceiling effects
were also analysed.
Study population
Once piloted, the Portuguese version was then tested for
reliability and validity. For this second phase we re-
cruited 100 patients and asked five psychiatrists from
the Psychiatric Hospital Centre, in Lisbon, to give the
questionnaires to patients. The sample size is considered
an acceptable number for validation studies and for
factor analysis [26]. Data were collected during a period
of 5 months, starting in December 2012.
The study population consisted of all individuals who
went for a consultation, in a consecutive way, having a
diagnosis of GAD according to DSM-IV-TR criteria [8],
and fulfilled the selection criteria outlined in the re-
search protocol. The diagnosis was made by psychia-
trists, based on clinical interview. The sample size was
estimated taking into account the sensitivity of the GAD
questionnaire. One hundred patients with GAD assure
that a 95% confidence interval around a sensitivity of
0.90 is not greater than 0.05.
As an inclusion criteria we accepted patients of both
genders, over 18 years old, able to understand and speak
Portuguese, with known diagnosis of generalized anxiety
disorder based on DSM-IV-TR [8], having anxiety symp-
toms with or without treatment. (score ≥ 20 points on
STAI anxiety scale). Patients with health conditions that
made them impossible to fill the scale without any help,
with limited knowledge of the Portuguese language,
illiterate, or under pharmacological treatment that inter-
fere with their ability to understand and answer the
questions, were excluded.
Reliability
The reliability was tested by a 1-week test-retest. A sam-
ple of 30 patients were given the GAD-7 in those two
different points in time and the Pearson, the item-total
and the intraclasse correlation coefficients were com-
puted. No clinical intervention occurred during this
week. With the whole sample we also determined the in-
ternal consistency through the Cronbach’s alpha coeffi-
cient [27].
Validity
In what concerns the validity tests, other official Portuguese
validated versions of measurement instruments were imple-
mented, namely, the self-administered generic quality of life
instrument EuroQoL EQ-5D [28-30], the Hospital Anxiety
and Depression Scale (HADS) [31,32] and the State-
Trait Anxiety Inventory (STAI) [33], in their validated
Portuguese versions. For the characterization of target
population we also collected socio-demographic data
(gender, age, educational level, family status and em-
ployment status) and some clinical data (clinical back-
ground, psychiatric and physical symptoms). The data
were collected by psychiatrists.
The generic EQ-5D instrument was originally devel-
oped in the University of York, UK, and allows us to
measure the global value that each individual assigns to
his/her health status. It also yields to the construction of
the utility indicator QALY (Quality-Adjusted Life Years)
used on clinical and policy decision-making [28]. The
dimensions measured by this instrument’s descriptive
system are (i) mobility, (ii) self-care, (iii) usual activities,
(iv) pain/discomfort, and (v) anxiety/depression. Each
dimension is scored in a 3-item severity scale and an
econometric algorithm produces an index ranging from
−0.59 to 1.00 (negative scores meaning health states
perceived as worse than death) and respecting the value
set that society assign to each measured health status.
EQ-5D also includes a visual analogue scale (VAS) de-
signed to look like a vertical thermometer, ranging from
0, meaning the worst imaginable health state, to 100,
meaning the best imaginable health state.
HADS aims to determine the levels of anxiety and
depression that a patient is experiencing. It is composed
by seven items relate to anxiety and seven other items
related to depression. An important point that distin-
guishes HADS from other scales is that, to prevent the
interference of somatic disorders on the scale score, all
the symptoms of anxiety or depression related to phys-
ical diseases were deleted. Each item is scored from 0 to
3 and the maximum total score is 21 for each subscale.
Also, again for each subscale, the authors proposed a
cut-off point such that a score smaller than 9 corre-
sponds to the absence of symptom and a score equal to
9 or higher corresponds to the presence of the symptom.
STAI is a self-reported measure that distinguishes be-
tween temporary condition of state anxiety and the long-
standing quality of trait anxiety. It takes about 10 minutes
to be filled and consists of two subscales, each of them
containing 20 items: (i) the S-Anxiety to evaluate the
current state of anxiety, and (ii) the T-Anxiety to evaluate
the relatively stable aspects of “anxiety proneness” (trait).
For each of these subscales the scores are added, although
some of them need to be reversed, the total scores range
from 20 and 80, where a high score indicates greater
anxiety.
To test the construct validity, we assessed the relation-
ship between the GAD-7 and the scores of socio-
demographic and clinical variable. Moreover, to test the
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unidimensionality of GAD-7 an exploratory principal
component factor analysis [34] was performed. Kaiser-
Meyer-Olkin (KMO) measure of sampling adequacy and
Bartlett’s test of sphericity were computed before the
factor analysis.
To test the criterion validity GAD-7 scores were com-
pared with the scores obtained by the other health status
and quality of life measures. Concordances between cri-
teria were computed by correlation coefficients and
chi-square independence tests.
Besides these tests previously referred, we also per-
formed descriptive analyses including measures of cen-
tral tendency and dispersion.
This study followed the basic ethical principles set by
the Declaration of Helsinki and has been approved by
the Ethics Board of the Lisbon Psychiatric Hospital. All
participants signed an informal consent, without any
benefits. Data collection was anonymous, without any
reference to patients personal identity, which was
encoded in all study documents.
Results
The sample
Table 1 shows the distributions of the main socio-
demographic and clinical variables.
Table 1 Socio-demographic and clinical variables
Variable Value N %
Sample 100 100.0
Gender Female 78 78.8
Male 21 21.2
Age Mean ± sd 52.2 ± 13.5
Min – Max 21 - 78
Education ≤4 years 44 44.9
5 to 9 years 22 22.4
10-12 years 21 21.4
>12 years 11 11.2
Family status Single 11 11.0
Married/Living together 38 68.0
Divorced 17 17.0
Widowed 4 4.0
Employment status Employed 32 32.3
Unemployed/Student 21 21.2
Retired 40 40.4
Sick leave 6 6.1
Clinical background Yes 59 59.0
No 41 41.0
Psychiatric background Yes 80 80.8
No 19 19.2











1A patient may have more than one symptom.
Table 2 Quality of life variables
Variable Dimension N %
GAD-7 Index Normal 4 4.0
Mild anxiety 7 7.1
Moderate anxiety 18 18.2
Severe anxiety 70 70.7
Mean ± sd 15.7 ± 4.6
Min - Max 2 - 21
EQ-5D Index [−0.50; −0.25] 2 2.0
[−0.25; 0.00] 1 1.0
[ 0.00; +0.25] 17 17.2
[+0.25; +0.50] 33 33.3
[+0.50; +0.75] 27 27.3
[+0.75; +1.00] 19 19.2
Mean ± sd 0.46 ± 0.29
Min - Max −0.37 - 1.00
VAS [ 0; 25] 17 17.9
[25; 50] 29 30.5
[50; 75] 40 42.1
[75; 100] 9 9.5
Mean ± sd 44.33 ± 22.27
Min - Max 0 - 95
HADS Anxiety Without symptoms 12 12.0
With symptoms 88 88.0
Mean ± sd 13.6 ± 4.2
Min - Max 1 - 21
Depression Without symptoms 31 31.0
With symptoms Mean 69 69.0
Mean ± sd 10.8 ± 4.4
Min - Max 0 - 21
STAI State Anxiety Mean ± sd 48.5 ± 4.3
Min - Max 39 - 61
Trait Anxiety Mean ± sd 50.5 ± 4.9
Min - Max 38 - 60
sd: standard deviation Min/Max: Minimum/Maximum.
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The sample included 78.8% of female with a mean age
of 52.2 ± 13.5. Regarding the education, 44.9% had, at
most, four years of schooling, 32.3% were employed and
68.0% were married or lived together. Among these pa-
tients, 59.0% had a previous clinical diagnosis and 80.8%
a previous psychiatric diagnosis. In what concerns phys-
ical symptoms, the highest prevalent were palpitations,
pain, headaches, and sudoresis.
Table 2 presents the distributions of the health status,
symptoms and health-related quality of live variables.
Regarding the health status and quality of life, the ma-
jority of the patients (70.7%) may be classified as severely
anxious, which is evidenced by the self-perception given
by the EQ-5D: mean index = 0.46 and mean VAS =
44.33. More than four fifth of the patients (88.0%) had
symptoms of anxiety and 69.0% showed symptoms of
depression. Accordingly, both the state and trait anxiety
scores were median, indicating a moderate form of
anxiety.
Feasibility
The mean GAD-7 completion time was 2.3 ± 1.3 minutes,
ranging from 30 seconds to 4.7 minutes. All items were
filled. To assess the floor and ceiling effects of GAD-7
we analysed the distribution of each item (see Table 3).
No major floor effect was found. In fact, only items 5
and 7 had a percentage higher than 8%. On the other
hand, our sample showed a group of patients with very
severe levels of anxiety.
Reliability
The Cronbach’s α obtained for the GAD’s seven items
was an excellent value (0.880) and it maintains excellent
even if we delete an item, as shown in the second col-
umn of Table 4.
Moreover, all items showed high item-total correlation
scores (column 3) and high test-retest correlation coeffi-
cients (column 4) and intraclass correlation coefficients
(column 5).
Construct validity
Table 5 shows the sensitivity of GAD-7 index over the differ-
ent values of the socio-demographic and clinical variables.
As we can draw from this table there is no significant
difference of GAD-7 index regarding gender, family sta-
tus, and clinical or psychiatric background. We also evi-
denced significant lower GAD-7 index, i.e., better health,
for younger (less than 40 years old) patients, those with
higher education, employed and without symptoms.
To test the construct validity we also performed a
principal component factor analysis and we evidenced
the desirable unidimensional structure, corresponding to
58.8% of explained variance.
GAD-7 index was correlated to the other health out-
come indices. Starting with EQ-5D, both indices had a
significant correlation (EQ-5D index: −0.538; VAS: −0.378).
However, the correlations with STAI indices were also
smaller, although significant (S-Anxiety: r = 0.378; T-
Anxiety: r = 0.353). In what concerns the HADS, GAD-
Table 3 Distribution of GAD-7 items
GAD-7 item Not at all Several days More than half the days Nearly every day
Feeling nervous, anxious or on edge 3.0% 10.1% 33.3% 53.5%
Not being able to stop or control worrying 1.0% 17.2% 24.2% 57.6%
Worrying too much about different things 2.0% 12.1% 33.3% 52.5%
Trouble relaxing 5.1% 12.1% 38.4% 44.4%
Being so restless that it is hard to sit still 8.1% 19.2% 34.3% 38.3%
Becoming easily annoyed or irritable 3.0% 17.2% 30.3% 49.5%
Feeling afraid as if something awful might happen 9.1% 13.1% 37.4% 40.4%
Table 4 Reliability indicators




Feeling nervous, anxious or on edge 0.854 0.817** 0.857** 0.819
Not being able to stop or control worrying 0.879 0.650** 0.576** 0.570
Worrying too much about different things 0.863 0.760** 0.677** 0.671
Trouble relaxing 0.852 0.828** 0.596** 0.555
Being so restless that it is hard to sit still 0.860 0.790** 0.629** 0.620
Becoming easily annoyed or irritable 0.867 0.739** 0.654** 0.644
Feeling afraid as if something awful might happen 0.865 0.764** 0.931** 0.930
**p < 0.01.
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7 showed to be better correlated with anxiety subscale
(r = 0.699) than with depression subscale (r = 0.450).
Comparing the anxiety classification obtained by
GAD-7, HADS-Anxiety and HAD-Depression measures
we noticed that they are not independent, meaning that
patients without symptoms revealed by both HADS
indices are also classified by GAD-7 as normal or with a
mild anxiety. The corresponding chi-squared values
(HADS-A: χ2 = 43.59; HADS-D: χ2 = 27.73) ware associ-
ated to p-values lower than 0.005.
On the other hand patients with symptoms detected
by HADS have always a higher GAD-7 index, as shown
in Table 6.
Discussion
The authors intended to test the culturally adapted into
Portuguese version of the GAD-7 scale concerning feasi-
bility, reliability and validity.
Excellent reliability values were found when compar-
ing each item of the measure with the total scores and
also in the test-retest, showing an excellent homogeneity
in concept measurement and stability between evalua-
tions over time.
We correlated the scores from GAD-7 with those from
HADS. As a result, we evidenced a very high significant
correlations with both HADS anxiety and depression
subscales, which supports the use of the GAD-7 as a
screening tool. However, regarding the STAI a signifi-
cant but weaker correlation was found probably due its
complexity.
When comparing the GAD-7 results with other health
outcome measures yielded from the EQ-5D scale, a rela-
tion was found between GAD assessments using the
scale and the disability level assessed by several domains
of daily life, which is in accordance with previous data
reported in GAD studies [35-37]. This shows that this
instrument is a solid tool for easily exploring patients
with GAD, establishing the level of severity, and linking
it to the degree of disability in the main areas of daily
living. Thus, GAD emerges as a strong predictor of func-
tional impairment [19].
The results obtained for the Portuguese version of the
GAD-7 and the impact of the socio-demographic char-
acteristics and clinical variables in the measurements were
in line with data available in the reviewed literature, with
exception of family status and clinical/psychiatric back-
ground. In our sample, anxiety levels were independent
from family status, with no significant difference between
single, married/living together, divorced and widowed.
Another unexpected result was that clinical and psychi-
atric background did not influence the results. This might
Table 5 Relationship between GAD-7 index and




Gender Female 15.96 1.14 0.256
Male 14.65
Age Less than 40 years 13.41 3.861 0.024
Between 40 and 59 years 16.45
60 or more years 16.30
Education ≤4 years 17.45 7.631 0.001
5 to 9 years 15.05
≥10 years 13.62
Family status Married/Living together 15.84 0.340 0.734
Not married 15.50
Employment status Employed 13.56 −0.3660 0.000
Non-employed 16.91




Yes 15.90 0.542 0.589
No 15.26
Pain Yes 17.33 3.514 0.001
No 14.39
Headache Yes 17.02 2.664 0.009
No 14.73
Tremors Yes 17.84 4.054 0.000
No 14.72
Palpitations Yes 16.78 2.181 0.032
No 14.81
Sudoresis Yes 17.15 2.625 0.010
No 14.76
Difficulty breathing Yes 18.09 2.848 0.005
No 15.05
Nausea Yes 18.21 2.242 0.027
No 15.32





Table 6 Comparison between GAD-7 index with HADS
Variable Value GAD-7 index t Sig
HADS – Anxiety Without symptoms 8.42 −7.329 0.000
With symptoms 16.74
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be due to the fact that the sample was merely clinical and
no general population controls were used.
Our study showed some limitations worth reviewing.
It was conducted in only one major psychiatric hospital.
However the authors consider it to be representative of
the existing linguistic variability in the country and,
therefore, sufficiently representative of the whole na-
tional territory. Additionally, a sample size of 100 pa-
tients and the absence of a control group may have
conditioned some results.
Another possible limitation might be the fact that
psychiatric diagnoses was performed through psychiatric
interview on clinical bases. Moreover, our sample con-
tained exclusively participants with a GAD diagnosis,
which may lead to a variance reduction and a risk of
underestimated correlation coefficients.
Despite the limitations, the good performance of the
scale adapted into Portuguese, its short administration
time and highly cost-effective administration make the
GAD-7 a useful tool for standard clinical practice for
patient screening purposes.
Conclusion
The GAD-7 scale has shown to be highly correlated not
only with specific anxiety measures but also with disabil-
ity measures showing excellent psychometric properties,
high discriminant ability, briefness, and fast administra-
tion. For these reasons, the successful validation into
Portuguese of the GAD-7 scale, will allow an increas-
ingly early detection and treatment of these patients,
thus improving their quality of life and reducing medical
and psychiatric complications.
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